Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
株式のランク #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
株価
$0.00047446
時価総額
$82.80
変化(1日)
0.00%
変化(1年)
-98.16%
FR
取引 Neovacs S.A. (ALNEV)

カテゴリー

Neovacs S.A.(ALNEV)のEPS
December 2024 時点のEPS TTM: $-34.55K
Neovacs S.A.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は$-34.55Kです。2023年末には、EPSは$-275.26Kで、2022年のEPS$-1.26と増加でした。
Neovacs S.A.のEPS履歴(2007から2026まで)
各年末時点のEPS
EPS 変化
2026 (TTM) $-34.55K 17,504.17%
2024 $-196.26 -99.93%
2023 $-275.26K 21,820,011.06%
2022 $-1.26 -100.00%
2021 $-5.367T -93.96%
2020 $-88.856T -79.32%
2019 $-429.767T -54.85%
2018 $-951.868T -52.78%
2017 $-2.02Qa -24.26%
2016 $-2.66Qa 115.81%
2015 $-1.23Qa -59.95%
2014 $-3.08Qa -17.40%
2013 $-3.73Qa -18.52%
2012 $-4.58Qa -9.86%
2011 $-5.08Qa -27.43%
2010 $-6.99Qa 21.97%
2009 $-5.73Qa 53.05%
2008 $-3.75Qa -7.11%
2007 $-4.03Qa 0.00%
同様の企業または競合他社のEPS
企業 EPS EPSの差
$3.62 -100.01%
DK
$15.47 -100.04%
US
$43.12 -100.12%
US
$9.62 -100.03%
BE
$38.32 -100.11%
NL